Impression Healthcare (ASX:IHL)

  • Symbol:ASX:IHL
  • Sector:Healthcare
  • Industry:Biotechnology
  • CEO:Joel Latham
  • Founded:2001

Impression Healthcare (ASX:IHL) Stock Price

Impression Healthcare (ASX:IHL) Company Overview

Impression Healthcare (ASX:IHL) started life as a manufacturer and supplier of custom-fit mouthguards, and other dental equipment. The Oral devices business continues to show strong revenue growth from all products; including, sports mouthguards for teeth protection and to reduce concussion risk, and sophisticated devices made to combat sleep apnoea, snoring and bruxism.

The other side of the company is a rapidly expanding Medicinal cannabis business with four unique clinical trials in partnership with Swinburne University of Technology, that are complementary to the issues they currently aim to prevent with the range of oral devices.

IHL's cannabinoid drug discovery brand Incannex Pharmaceuticals is a collaboration with an EU-based cannabinoid drug design company named Linnea SA. The EU-based company will serve as IHL's supply partner for the base cannabinoid materials in four novel cannabinoid formulations.

IHL has also secured Australian licenses in place to import, export and distribute cannabis products and access to Cannvalate – the largest network of cannabis medicine prescribers in Australia.

Impression Healthcare (ASX:IHL) Financials

More From Impression Healthcare...

You're Missing Out: 3 Top Cannabis Biotech Stocks
Exclusive Interview With Cannvalate CEO Dr. Sud Agarwal
Impression Healthcare Trials Cannabinoid Formula to Fight Sleep Apnoea
Drumroll Please – CWEB Announces Retail Distribution Deal with Kroger
Incannex Enters Into Medicinal Cannabis Oil Supply Agreement
Killer Instinct – Impression Healthcare Partners with ONE Championship
Time to Celebrate – Elixinol Publishes Q2 Results, Partners with PharmaCare and Secures Microencapsulation License
Impression Healthcare Extends Agreement With FiT To Study Concussions
Power Play – Impression Healthcare Announces Appointment of Dr Sud Agarwal
Sleep Tight: Impression Healthcare Trialing Cannabis Based Sleep Apnoea Cure
Load More Results

Investor Presentation

The latest update from the company

Click Here
Stay updated about
this company

Signup to get updates.


Joel Latham
Chief Executive Officer & Managing Director
Joel Latham has more than 13 years’ experience with blue chip firms including Mars Foods, Tabcorp and Philip Morris International. Prior to his appointment to CEO, Latham worked as the General Manager of Impression Healthcare for a three-year period.

During this time, he played an instrumental role in the marketing and procurement of multiple revenue-generating opportunities and collaborations, including with Pacific Smiles, the NRL, AFL and the implementation of Gameday’s ambassadorial program.
Glenn Fowles
Company Secretary
Glenn Fowles has 30 years of financial experience and has been responsible for a diverse array of duties, including accounting, tax, compliance, and the management of corporate entities.

He was previously employed by HSBC—where he acted as COO and Executive Director—as well as being the CFO and Company Secretary for Global Health Ltd.

Fowles also spent 17 years working with the boutique fund manager, Contango Asset Management Limited, where he took on a wide variety of roles, including executive director, COO and Company Secretary.
Troy Valentine
Troy Valentine is a financial professional with over 23 years’ experience in the world of stockbroking and corporate finance.

Valentine brings a broad range of experience and skills related to the management of ASX-listed emerging companies to his role as Chairman. Aside from his work with Impression Healthcare, Valentine is also the Executive Director of a boutique advisory firm, Alignment Capital Pty Ltd.
Dr. Sud Agarwal
Chief Medical Officer
Dr Sud Agarwal is an internationally recognised key opinion leader in the clinical use of medicinal cannabis is the co-founder and chief executive officer of Cannvalate.

Agarwal received his medical qualifications in the United Kingdom before immigrating to Australia in 2001. He has since played a key role in the commercialisation, scaling and successfully exiting of three healthcare businesses.